Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.
OBJECTIVE
To assess the efficacy of orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) and the impact of current staging criteria on long term survival.


BACKGROUND
HCC is becoming an increasingly common indication for OLT. Medicare approves OLT only for HCCs meeting the Milan criteria, thus limiting OLT for an expanding pool of potential liver recipients. We analyzed our experience with OLT for HCC to determine if expansion of criteria for OLT for HCC is warranted.


METHODS
: All patients undergoing OLT for HCC from 1984 to 2006 were evaluated. Outcomes were compared for patients who met Milan criteria (single tumor < opr =5 cm, maximum of 3 total tumors with none >3 cm), University of California, San Francisco (UCSF) criteria (single tumor <6.5 cm, maximum of 3 total tumors with none >4.5 cm, and cumulative tumor size <8 cm), or exceeded UCSF criteria.


RESULTS
A total of 467 transplants were performed for HCC. At mean follow up of 6.6 +/- 0.9 years, recurrence rate was 21.2%, and overall 1, 3, and 5-year survival was 82%, 65%, and 52%, respectively. Patients meeting Milan criteria had similar 5-year post-transplant survival to patients meeting UCSF criteria by preoperative imaging (79% vs. 64%; P = 0.061) and explant pathology (86% vs. 71%; P = 0.057). Survival for patients with tumors beyond UCSF criteria was significantly lower and was below 50% at 5 years. Multivariate analysis showed that tumor number (P < 0.001), lymphovascular invasion (P < 0.001), and poor differentiation (P = 0.002) independently predicted poor survival.


CONCLUSIONS
This largest single institution experience with OLT for HCC demonstrates prolonged survival after liver transplantation for tumors beyond Milan criteria but within UCSF criteria, both when classified by preoperative imaging and by explant pathology. Measured expansion of OLT criteria is justified for tumors not exceeding the UCSF criteria.
Duffy
John P
JP
Dumont-UCLA Transplant Center, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Vardanian
Andrew
A
Benjamin
Elizabeth
E
Watson
Melissa
M
Farmer
Douglas G
DG
Ghobrial
Rafik M
RM
Lipshutz
Gerald
G
Yersiz
Hasan
H
Lu
David S K
DS
Lassman
Charles
C
Tong
Myron J
MJ
Hiatt
Jonathan R
JR
Busuttil
Ronald W
RW
D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery*; D016009:Chi-Square Distribution; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018579:Patient Selection; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
Transplant Proc. 2003 Aug;35(5):1818-20
12962807
Ann Surg. 2005 Jun;241(6):905-16; discussion 916-8
15912040
Lancet. 2003 Dec 6;362(9399):1907-17
14667750
Ann Surg. 2004 Feb;239(2):150-9
14745321
Liver Transpl. 2004 Jan;10(1):36-41
14755775
Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20
14762851
Liver Transpl. 2004 Apr;10(4):534-40
15048797
Liver Transpl. 2004 Jul;10(7):886-97
15237373
Liver Transpl. 2004 Jul;10(7):911-8
15237377
Ann Surg. 2004 Sep;240(3):451-9; discussion 459-61
15319716
Magn Reson Med. 2000 Sep;44(3):433-9
10975896
Hepatology. 2001 Feb;33(2):464-70
11172350
Transplant Proc. 2001 Feb-Mar;33(1-2):1442-4
11267365
Hepatology. 2001 Jun;33(6):1394-403
11391528
Ann Surg. 2002 Apr;235(4):533-9
11923610
Liver Transpl. 2002 Sep;8(9):765-74
12200775
Liver Transpl. 2003 Apr;9(4):331-8
12682882
J Hepatol. 2005 Oct;43(4):558-62
16112246
Transplant Proc. 2005 Jul-Aug;37(6):2535-40
16182736
Liver Transpl. 2005 Dec;11(12):1505-14
16315294
Am J Gastroenterol. 2005 Dec;100(12):2708-16
16393224
Liver Transpl. 2006 Apr;12(4):665-73
16482577
Dig Dis Sci. 2006 Jun;51(6):1070-8
16865573
Liver Transpl. 2006 Dec;12(12):1761-9
16964590
Eur J Med Res. 2006 Nov 30;11(11):467-70
17182358
J Surg Oncol. 2007 Mar 1;95(3):235-40
17323337
Liver Transpl. 2007 Mar;13(3):391-9
17318865
Liver Transpl. 2007 Apr;13(4):543-51
17394152
World J Surg. 2007 Jun;31(6):1243-8
17440771
Liver Transpl. 2003 Jul;9(7):664-71
12827550
Liver Transpl. 2003 Jul;9(7):693-6
12827554
Liver Transpl. 2004 Sep;10(9):1195-202
15350014
Liver Transpl. 2004 Oct;10(10):1301-11
15376305
Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34
15508094
Liver Transpl. 2004 Nov;10(11):1343-54
15497158
Ann Surg. 1987 Oct;206(4):387-402
3310930
World J Surg. 1991 Mar-Apr;15(2):270-85
1851588
Ann Surg. 1991 Sep;214(3):221-8; discussion 228-9
1656903
J Surg Oncol Suppl. 1993;3:78-82
8389178
Ann Surg. 1993 Aug;218(2):145-51
8393649
Transplant Proc. 1995 Aug;27(4):2296-8
7652813
N Engl J Med. 1996 Mar 14;334(11):693-9
8594428
Hepatology. 1998 Jun;27(6):1572-7
9620329
Ann Surg. 1998 Oct;228(4):479-90
9790338
N Engl J Med. 1999 Mar 11;340(10):745-50
10072408
Cancer. 1954 May;7(3):462-503
13160935
Magn Reson Med. 2005 Mar;53(3):621-7
15723405
Am J Transplant. 2005 Apr;5(4 Pt 1):795-804
15760404
Hepatology. 2005 May;41(5):1130-7
15841454
Transplant Proc. 2003 Nov;35(7):2438-41
14611981